The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
Key facts
- Who runs it
- National Taiwan University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jan 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Record updated
- 7 May 2026
- Why it stopped
- Administrative withdrawal: This study was determined to be a continuation of \[NCT05718336\]. To avoid duplicate reporting and ensure consistent publication, this record is being consolidated into the prior study. No enrollment has occurred.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- -Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)
Who cannot take part
- -Subjects without complete pre- and post-treatment testing
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Read full original descriptionShow less
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
The group in the trial
- afib
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 May 2026